Cozad Asset Management Inc. raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,177 shares of the medical research company’s stock after buying an additional 379 shares during the quarter. Thermo Fisher Scientific accounts for about 2.1% of Cozad Asset Management Inc.’s holdings, making the stock its 4th biggest position. Cozad Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $6,891,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in TMO. Capital Financial Planning LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $27,000. Hanson McClain Inc. grew its position in Thermo Fisher Scientific by 263.9% in the fourth quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock worth $29,000 after acquiring an additional 95 shares in the last quarter. Truvestments Capital LLC bought a new stake in Thermo Fisher Scientific in the first quarter worth approximately $29,000. Capital Investment Advisory Services LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $35,000. Finally, Liberty Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 88.66% of the company’s stock.
NYSE TMO opened at $259.78 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. The firm has a market cap of $103.65 billion, a P/E ratio of 23.36, a PEG ratio of 1.83 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 1 year low of $202.83 and a 1 year high of $282.98.
The business also recently declared a quarterly dividend, which was paid on Tuesday, April 16th. Shareholders of record on Friday, March 15th were issued a $0.19 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is 6.83%.
In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 19,808 shares of the stock in a transaction on Monday, February 25th. The shares were sold at an average price of $253.29, for a total value of $5,017,168.32. Following the completion of the sale, the senior vice president now directly owns 25,688 shares of the company’s stock, valued at approximately $6,506,513.52. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Gregory J. Herrema sold 5,400 shares of the stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $251.51, for a total transaction of $1,358,154.00. Following the completion of the sale, the senior vice president now directly owns 31,846 shares of the company’s stock, valued at $8,009,587.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 36,927 shares of company stock valued at $9,388,124. Insiders own 0.49% of the company’s stock.
Several analysts have commented on the stock. BTIG Research boosted their target price on shares of Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 30th. Needham & Company LLC initiated coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 2nd. They set a “strong-buy” rating and a $271.00 price objective for the company. Bank of America reaffirmed a “buy” rating and set a $300.00 price objective (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Finally, UBS Group upped their price objective on shares of Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $289.92.
ILLEGAL ACTIVITY NOTICE: “Thermo Fisher Scientific Inc. (TMO) is Cozad Asset Management Inc.’s 4th Largest Position” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/thermo-fisher-scientific-inc-tmo-is-cozad-asset-management-inc-s-4th-largest-position.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What are the qualifications of a portfolio manager?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.